Skip to main content
SpringerLink
Log in

SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know

  • Commentary
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67.

    Article  CAS  PubMed  Google Scholar 

  2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 aha/acc/hfsa guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e263–421.

    Article  PubMed  Google Scholar 

  3. Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the deliver randomized clinical trial. JAMA Cardiol. 2022;7(12):1259–63.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O’Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;78:2004–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Salah HM, Al’Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10–22.

    Article  CAS  PubMed  Google Scholar 

  6. Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Efficacy and safety of sglt2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7:3298–309.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Butt JH, Jhund PS, Belohlavek J, de Boer RA, Chiang CE, Desai AS, Drozdzz J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Langkilde AM, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderang U, Claggett BL, Solomon SD, McMurray JJV. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the deliver trial. Circulation. 2022;146(16):1210–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zheng J, Parizo JT, Spertus JA, Heidenreich PA, Sandhu AT. Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction. JAMA Intern Med. 2022;182:1278–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cohen LP, Isaza N, Hernandez I, Lewis GD, Ho JE, Fonarow GC, Kazi DS, Bellows BK. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023;8:419–28.

    Article  PubMed  Google Scholar 

  10. Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, McGrath MM, O’Meara E, Wilderang U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022;80(14):1302–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, 300 West Morgan Street, Durham, NC, 27701, USA

    Stephen J. Greene

  2. Division of Cardiology, Duke University School of Medicine, Durham, NC, USA

    Stephen J. Greene

  3. Division of Cardiology, Department of Medicine, Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA

    Gregg C. Fonarow

  4. Baylor Scott and White Research Institute, Dallas, TX, USA

    Javed Butler

  5. Department of Medicine, University of Mississippi, Jackson, MS, USA

    Javed Butler

Authors
  1. Stephen J. Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregg C. Fonarow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen J. Greene.

Ethics declarations

Conflict of interest

Dr. Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association (#929502), Amgen, AstraZeneca, Boehinger Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics. Dr. Fonarow serves as a consultant for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Eli Lilly, Janssen, Medtronic, Merck, Novartis, and Pfizer. Dr. Butler serves as a consultant for Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Daxor Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Roche, Secretome, Sequana, SQ Innovation, Tenex, and Vifor.

Funding

No external funding was used in the preparation of this manuscript.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Data availability statement

Data sharing not applicable to this article as no datasets were generated to prepare this manuscript.

Code availability

Not applicable.

Author contributions

All authors participated in the writing, reviewing, and editing of this manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greene, S.J., Fonarow, G.C. & Butler, J. SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know. Am J Cardiovasc Drugs 24, 1–4 (2024). https://doi.org/10.1007/s40256-023-00624-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-023-00624-2

Search

Navigation